BioSpace News Archive

Research shows that uproleselan is a potent antagonist of E-selectin, can break chemoresistance

Pathline Labs, a leading provider of sub-specialized anatomic pathology, has developed Coronavirus Disease testing at its Ramsey, New Jersey facility.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has received a No Objection Letter from Health Canada to proceed with a NP-120 (Ifenprodil) COVID-19 Phase 2b/3 multinational clinical trial. The same study protocol is being prepared for submission to the U.S. FDA and Australian regulatory au

New Online Hub Dedicated to Raising Awareness and Educating New Parents on the Benefits of Early Introduction [30-April-2020] MCLEAN, Va. , April 30, 2020 /PRNewswire/ -- Today, FARE (Food Allergy Research & Education), the world’s leading food allergy advocacy organization and the largest private funder of food allergy research, announced the launch of a new reso

Data presented on repurposing the existing, broad-spectrum antiviral agent using Thin Film Freezing and other techniques to enhance its effect for COVID-19 therapy

In the race to find treatment options for COVID-19 patients, physicians and clinicians began treating the virus as they would viral pneumonia.

BostonGene Corporation, a biomedical software company focused on defining optimal precision medicine-based therapies for cancer patients, today announced it has expanded its research collaboration with Washington University in St. Louis to study renal cell carcinoma (RCC). This collaboration will evaluate t

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has posted its Annual Report prepared in accordance with IFRS accounting standards for the year ended December 31, 2019 on its website. This report, which is only for statutory purposes, can be accessed on QIAGEN’s website at: https://corporate.qiagen.com/investor-relations/financial-reports/other-reports QIAGEN N.V. further announc

Nines Makes AI to Detect Emergent Conditions Available Free To Customers Including Those Overwhelmed By COVID-19 Diagnostics

BioSig Technologies, Inc. announced that an article titled, “The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro”, was submitted to an online peer-reviewed life sciences journal.